FDA review of oral MS drug FTY720 extended
FDA review of oral MS drug FTY720 extended
Novartis International AG / Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapy.
* US Food and Drug Administration (FDA) extends priority review period by three months to September 2010, in line with previously announced expectations............. [Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309 ]
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1748 Views
-
Last post by frodo
-
- 0 Replies
- 1845 Views
-
Last post by NHE
-
- 1 Replies
- 1497 Views
-
Last post by frodo
-
- 0 Replies
- 1575 Views
-
Last post by frodo
-
- 0 Replies
- 1100 Views
-
Last post by frodo
-
- 0 Replies
- 1109 Views
-
Last post by NHE
-
- 0 Replies
- 2110 Views
-
Last post by NHE
-
- 0 Replies
- 1653 Views
-
Last post by frodo
-
- 0 Replies
- 963 Views
-
Last post by frodo